| Cat No. | Product Name | Information | Reference |
|---|---|---|---|
| S4430 | Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate is an antimalarial agent used for the treatment of systemic lupus erythematosus, rheumatoid arthritis and other autoimmune, inflammatory and dermatologic conditions. Also acts as an inhibitor of autophagy and toll-like receptor (TLR) 7/9. | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial |
| S2853 | Carfilzomib (PR-171) | Carfilzomib (PR-171) is an irreversible proteasome inhibitor with IC50 of <5 nM in ANBL-6 cells, displayed preferential in vitro inhibitory potency against the ChT-L activity in the β5 subunit, but little or no effect on the PGPH and T-L activities. | Fast Identification of Possible Drug Treatment of Coronavirus Disease -19 (COVID-19) Through Computational Drug Repurposing Study |
| S7975 | Favipiravir (T-705) | Favipiravir (T-705) is a potent and selective RNA-dependent RNA polymerase inhibitor, used to treat influenza virus infections. | Discovering drugs to treat coronavirus disease 2019 (COVID-19) |
| S1835 | Azithromycin | Azithromycin is an antibiotic by inhibiting protein synthesis, used for the treatment of bacterial infections. | Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial |
| S1620 | Darunavir Ethanolate | Darunavir Ethanolate (DRV) is a nonpeptidic HIV protease inhibitor, used to treat HIV infection. | Many drugs already approved by FDA may have promise against COVID-19 |
| S4646 | Ciclesonide | Ciclesonide is a glucocorticoid used to treat obstructive airway diseases. | Therapeutic potential of ciclesonide inahalation for COVID-19 pneumonia: Report of three cases |
| S3035 | Daunorubicin HCl | Daunorubicin HCl inhibits both DNA and RNA synthesis and inhibits DNA synthesis with Ki of 0.02 μM in a cell-free assay. | Many drugs already approved by FDA may have promise against COVID-19 |
| S4157 | Chloroquine diphosphate | Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator. | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |
| S2823 | Tideglusib | Tideglusib is an irreversible, non ATP-competitive GSK-3β inhibitor with IC50 of 60 nM in a cell-free assay; fails to inhibit kinases with a Cys homologous to Cys-199 located in the active site. Phase 2. | Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors |
| S2874 | Camostat Mesilate | Camostat is a trypsin-like protease inhibitor, inhibits airway epithelial sodium channel (ENaC) function with IC50 of 50 nM, less potent to trpsin, prostasin and matriptase. | The Impact of Camostat Mesilate on COVID-19 Infection (CamoCO-19) |
| S8932 | Remdesivir (GS-5734) | Remdesivir,a monophosphoramidate prodrug of an adenosine analog, is an investigational broad-spectrum antiviral agent with in vitro activity against multiple RNA viruses, including Ebola and CoV. | Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro |
| S5911 | Bictegravir | Bictegravir is a novel, potent, once-daily, unboosted inhibitor of HIV-1 integrase. | Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches |
| S1759 | Pitavastatin Calcium | Pitavastatin calcium, a novel member of the medication class of statins, is a calcium salt formulation of pitavastatin which is a highly effective HMG-CoA reductase inhibitor. | Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches |
| S1680 | Disulfiram | Disulfiram is a specific inhibitor of aldehyde-dehydrogenase (ALDH1), used for the treatment of chronic alcoholism by producing an acute sensitivity to alcohol. | Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors |
| S1386 | Nafamostat Mesylate | Nafamostat mesilate is a synthetic serine protease inhibitor, used as an anticoagulant during hemodialysis. | Nafamostat inhibits SARS-CoV-2 infection, preventing COVID-19 transmission |
| S1706 | Lamivudine | Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor, used for treatment of chronic HBV and HIV/AIDS. It works by blocking the HIV reverse transcriptase and hepatitis B virus polymerase. | |
| S8279 | Shikonin | Shikonin, a potent and specific Pyruvate kinase M2 (PKM2) inhibitor, is a major component of zicao (purple gromwell, the dried root of Lithospermum erythrorhizon), a Chinese herbal medicine with various biological activities. It is also an inhibitor of TMEM16A chloride channel activity using cell-based fluorescent-quenching assay. | |
| S1380 | Lopinavir | Lopinavir is a potent HIV protease inhibitor with Ki of 1.3 pM in a cell-free assay. | Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicin |
| S2485 | Mitoxantrone 2HCl | Mitoxantrone is a type II topoisomerase inhibitor with IC50 of 2.0 μM, 0.42 mM for HepG2 and MCF-7/wt cells, respectively. | Many drugs already approved by FDA may have promise against COVID-19 |
| S4282 | Nelfinavir Mesylate | Nelfinavir Mesylate is a potent HIV protease inhibitor with Ki of 2 nM. | Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches |
| S1185 | Ritonavir | Ritonavir is a Cytochrome P450 3A and Protease Inhibitor; Also inhibits Cytochrome P450 2D6, P-Glycoprotein and induces Cytochrome P450 2C19, Cytochrome P450 1A2, Cytochrome P450 2C9, Cytochrome P450 2B6 and UDP Glucuronosyltransferases. | Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicin |
| S1351 | Ivermectin | Ivermectin is a glutamate-gated chloride channel (GluCls) activator, used as a broad-spectrum antiparasitic drug. | |
| S1401 | Tenofovir | Tenofovir blocks reverse transcriptase and hepatitis B virus infections. | |
| S5072 | Rosuvastatin | Rosuvastatin is an inhibitor of HMG-CoA reductase, an enzyme that catalyzes the rate-limiting step in cholesterol biosynthesis, with Ki value (inhibition constant) of approximately 0.1 nM. | Many drugs already approved by FDA may have promise against COVID-19 |
| S5250 | Darunavir | Darunavir is a nonpeptidic HIV protease inhibitor, used to treat HIV infection. | Many drugs already approved by FDA may have promise against COVID-19 |
| S7579 | Ledipasvir (GS5885) | Ledipasvir (GS5885) is a HCV NS5A polymerase inhibitor, used for the treatment of hepatitis C virus infection. | Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repur |
| S1538 | Telaprevir (VX-950) | Telaprevir (VX-950) is an HCV NS3-4A serine protease inhibitor with IC50 of 0.35 μM. | α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment |
| S1183 | Danoprevir (ITMN-191) | Danoprevir(ITMN-191) is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A. Phase 2. | First Clinical Study Using HCV Protease Inhibitor Danoprevir to Treat Naive and Experienced COVID-19 Patients |
| S2169 | Rosuvastatin Calcium | Rosuvastatin Calcium is a competitive inhibitor of HMG-CoA reductase with IC50 of 11 nM in a cell-free assay. | Many drugs already approved by FDA may have promise against COVID-19 |
| S1289 | Carmofur | Carmofur is a highly potent acid ceramidase inhibitor, used in the treatment of breast and colorectal cancer. | |
| S7947 | PX-12 | PX-12 is a potent thioredoxin-1 (Trx-1) inhibitor by irreversibly thioalkylation of Cys73 of Trx-1. Phase 2. | Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors |
| S3079 | Atovaquone | Atovaquone is a medication used to treat or prevent for pneumocystis pneumonia, toxoplasmosis, malaria, and babesia. | Many drugs already approved by FDA may have promise against COVID-19 |
| S2926 | TDZD-8 | TDZD-8 is a non-ATP competitive GSK-3β inhibitor with IC50 of 2 μM; minimal inhibitory effect observed on CDK1, casein kinase II, PKA and PKC. | Structure of M pro From COVID-19 Virus and Discovery of Its Inhibitors |
| S1691 | Praziquantel | Praziquantel is an anthelmintic effective against flatworms. | Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches |
| S3733 | Boceprevir | Boceprevir is an oral, direct acting hepatitis C virus (HCV) protease inhibitor with Ki value of 14 nM for NS3. It is used in combination with other antiviral agents in the treatment of chronic hepatitis C, genotype 1. | α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment |
| S3724 | Velpatasvir | Velpatasvir is a second-generation NS5A inhibitor that inhibits hepatitis C viral replication through acting on the crucial “membranous web” that facilitates RNA replication. | Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL pro) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repur |
| S2071 | Prulifloxacin (NM441) | Prulifloxacin, the prodrug of ulifloxacin, is a broad-spectrum oral fluoroquinolone antibacterial agent. | Potential COVID-2019 3C-like Protease Inhibitors Designed Using Generative Deep Learning Approaches |
| S9567 | Indinavir Sulfate | Indinavir sulfate is a specific and potent inhibitor of HIV-1 protease and is widely used in the treatment of AIDS. | Potential Therapeutic Agents for COVID-19 Based on the Analysis of Protease and RNA Polymerase Docking |
| S2079 | Moexipril HCl | Moexipril HCl is a potent orally active nonsulfhydryl angiotensin converting enzyme (ACE) inhibitor, used for the treatment of hypertension and congestive heart failure. | Many drugs already approved by FDA may have promise against COVID-19 |
| S3037 | Bepotastine Besilate | Bepotastine is a non-sedating, selective antagonist of histamine 1 (H1) receptor with pIC50 of 5.7. | Many drugs already approved by FDA may have promise against COVID-19 |
| S5940 | Bepotastine | Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor that is indicated in allergic rhinitis, urticaria, and pruritus associated with skin disease. | Many drugs already approved by FDA may have promise against COVID-19 |
| S6676 | Ebselen | Ebselen is a small-molecule capsid inhibitor of HIV-1 Replication with IC50 of 46.1 nM in TR-FRET assay. |
